Status:
COMPLETED
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effect...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 2 Diabetes for more than 12 months
- Currently treated with glucose lowering tablets or insulin
- HbA1c: 7.0-12.0%
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
389 Patients enrolled
Trial Details
Trial ID
NCT00106366
Start Date
March 1 2005
End Date
December 1 2005
Last Update
January 31 2017
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35235
2
Novo Nordisk Investigational Site
Vestavia Hills, Alabama, United States, 35209
3
Novo Nordisk Investigational Site
Little Rock, Arkansas, United States, 72204
4
Novo Nordisk Investigational Site
Searcy, Arkansas, United States, 72143